The Novartis Oncology commitment, drive and passion can be described with one word: hungry
Nov 30, 2015
By Bruno Strigini, President, Novartis Oncology
At this year’s American Society of Hematology (ASH) Annual Meeting, the hematology community will come together to unveil the latest information, data and research in many different types of blood-related disorders, including blood cancers like leukemia, lymphoma and myeloma. I am always energized by these meetings, and the passion that everyone involved with the studies presented bring. I know that we at Novartis Oncology, along with our researchers, work tirelessly to discover and develop new cancer treatments. The commitment, drive and passion can be described with one word: hungry.
We at Novartis Oncology are hungry for information, science, data, and, most of all, cures. We are hungry because patients and their families are desperately waiting for new treatments that can help them live better and live longer. It’s this hunger that keeps us going. When treatments don’t work, we keep on trying and when they work just fine, we look at how we may be able to make them better. We look at problems from different angles and try to find the solution in places you’d least expect, so that patients have as many options in their treatment arsenal as they continue to fight these diseases.
Our long-standing experience in treating blood cancers puts us in a unique position to help patients with many types of leukemias, lymphomas and myelomas. I’m excited to see what we, alongside the hematology research community, can accomplish at this year’s meeting.